PCI-34051

For research use only. Not for use in humans.

目录号：S2012

CAS No. 950762-95-5

PCI-34051是一种有效的，特异性的HDAC8抑制剂，无细胞试验中IC50为10 nM。比作用于HDAC1和6选择性高200多倍，比作用于HDAC2， 3，和10选择性高1000倍。PCI-34051可诱导半胱天冬酶依赖的凋亡。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 1815.22	现货
10mg	RMB 1377.26	现货
100mg	RMB 9582.3	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的PCI-34051发表文献38篇：

Nat Biotechnol, 2015, 10.1038/nbt.3130

PubMed: 25751058 ( click the link to review the publication )

Thyroid, 2021, 10.1089/thy.2020.0948

PubMed: 34235979 ( click the link to review the publication )

Tuberculosis (Edinb), 2021, 127:102062

PubMed: 33639591 ( click the link to review the publication )

Nat Commun, 2020, 11(1):5783

PubMed: 33188197 ( click the link to review the publication )

Theranostics, 2020, 10(15):6790-6805

PubMed: 32550904 ( click the link to review the publication )

Cell Death Dis, 2020, 11(12):1036

PubMed: 33279948 ( click the link to review the publication )

FASEB J, 2020, 12

PubMed: 32281211 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(12):E4539

PubMed: 32630606 ( click the link to review the publication )

Am J Transl Res, 2020, 12(10):6187-6203

PubMed: 33194023 ( click the link to review the publication )

EXCLI J, 2020, 19:734-744

PubMed: 32636726 ( click the link to review the publication )

Sci Rep, 2020, 10(1):12864

PubMed: 32733053 ( click the link to review the publication )

Theranostics, 2020, 10(16):7351-7368

PubMed: 32641996 ( click the link to review the publication )

Pathol Res Pract, 2020, 216(4):152867

PubMed: 32067803 ( click the link to review the publication )

Aging (Albany NY), 2020, 12(14):14174-14188

PubMed: 32692721 ( click the link to review the publication )

Cancer Res, 2019, 79(11):2947-2961

PubMed: 30987999 ( click the link to review the publication )

Cell Rep, 2019, 26(10):2608-2621.e6

PubMed: 30840885 ( click the link to review the publication )

Cancers (Basel), 2019, 11(5)E645

PubMed: 31083396 ( click the link to review the publication )

PLoS Genet, 2019, 15(2):e1007685

PubMed: 30779731 ( click the link to review the publication )

Biol Chem, 2019, 400(6):733-743

PubMed: 30521473 ( click the link to review the publication )

Nucl Med Biol, 2019, 74-75:1-11

PubMed: 31421440 ( click the link to review the publication )

Clin Hypertens, 2019, 25:13

PubMed: 31223486 ( click the link to review the publication )

Cancer Res, 2018, 78(20):5731-5740

PubMed: 30135193 ( click the link to review the publication )

J Med Chem, 2018, 61(22):10000-10016

PubMed: 30347148 ( click the link to review the publication )

Stem Cells Transl Med, 2018, 10.1002/sctm.18-0057

PubMed: 30426726 ( click the link to review the publication )
Oncol Rep, 2018, 40(2):635-646

PubMed: 29917168 ( click the link to review the publication )

Virol Sin, 2018, 33(5):418-428

PubMed: 30328580 ( click the link to review the publication )

Exp Mol Med, 2017, 49(2):e297

PubMed: 28232663 ( click the link to review the publication )

Chemistry, 2017, 23(13):3107-3116

PubMed: 27922200 ( click the link to review the publication )

Int J Mol Sci, 2017, 18(5)

PubMed: 28481295 ( click the link to review the publication )

PLoS One, 2017, 12(10):e0186620

PubMed: 29045501 ( click the link to review the publication )

ACS Chem Biol, 2016, 11(10):2685-2692

PubMed: 27459069 ( click the link to review the publication )

J Cell Mol Med, 2016, 20(12):2289-2298

PubMed: 27420561 ( click the link to review the publication )

Horm Cancer, 2016, 7(3):196-210

PubMed: 26957440 ( click the link to review the publication )

Nat Microbiol, 2016, 1:16174

PubMed: 27694949 ( click the link to review the publication )

J Immunol, 2015, 195(11):5421-31

PubMed: 26519528 ( click the link to review the publication )

Cancer Immunol Res, 2015, 3(12):1375-85

PubMed: 26297712 ( click the link to review the publication )

BMC Biol, 2014, 12:95

PubMed: 25406762 ( click the link to review the publication )

J Mol Biol, 2014, 426(20):3442-53

PubMed: 24657767 ( click the link to review the publication )

产品安全说明书

HDAC抑制剂选择性比较

生物活性

产品描述

靶点

HDAC8 ^[1]
(Cell-free assay)

10 nM

体外研究

PCI-34051有效作用于HDAC8，K_i为10 nM。与其他I型HDACs包括HDAC1相比，PCI-34051更高选择性作用于HDAC8。比作用于HDAC1和HDAC6选择性高200倍，比作用于 HDAC2, HDAC3 和HDAC10选择性高1000倍。PCI-34051抑制卵巢瘤细胞系OVCAR-3，GI50为6 μM，细胞死亡率为15%。PCI-34051浓度低于25 μM 时，处理敏感细胞系，在24小时而非更早时间点，观察不到显著的微管蛋白，也观察不到组蛋白乙酰化。PCI-34051 作用于T细胞恶性肿瘤衍生的细胞系，诱导选择性的细胞毒性作用。PCI-34051 诱导caspase依赖性凋亡。使用5 μM PCI-34051处理后，在不同时间点测量caspase-3活性, 在12 到24 到48 小时观察到活性水平提高，凋亡的另一种标志, 与更高水平caspase 活性一致。PCI-34051不刺激 Bid 分裂, Bid 分裂是外在凋亡通路的特性影响。P116 和 J.RT3-T.5 对PCI-34051敏感，PLCγ1缺陷的J.gamma1系显著降低 PCI-34051诱导凋亡的程度。此外, 稳定的钙水平也强烈影响PCI-34051诱导的凋亡。PCI-34051诱导细胞色素 c从线粒体中释放。^[1]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
LAN1	MljZS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M2\X[lczKGi{cx?=	NX;SeFNRT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hVEGQMTDj[YxteyCrbnP1ZoF1\WRiZn;yJFczKGi{czDifUBOXFNiYYPzZZktKEeLNUC9N{46\|ryP	NXjLWZFqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOxNVYyPDdpPkKzNVE3OTR5PD;hQi=>
Jurkat	NEnNVoxIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MUK3NkBpenN?	MVLHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDKeZJs[XRiY3XscJMhcW6ldXLheIVlKG[xcjC3NkBpenNiYomgUXRUKGG\|c3H5MEBIUTVyPUGx{txO	M2nibVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MUG2NVQ4Lz5{M{GxOlE1PzxxYU6=
NB-1	MojMS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M{TjWVczKGi{cx?=	Ml\uS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gUmIuOSClZXzsd{BqdmO3YnH0[YQh\m:{IEeyJIhzeyCkeTDNWHMh[XO\|YYmsJGdKPTB;MUVOwG0>	MkjUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNzMU[xOFcoRjJ\|MUG2NVQ4RC:jPh?=
MT2	NELVcZhIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NV3UNnJ6PzJiaILz	NIX2N5lIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBOXDJiY3XscJMhcW6ldXLheIVlKG[xcjC3NkBpenNiYomgUXRUKGG\|c3H5MEBIUTVyPUG1{txO	NVrycWJxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOxNVYyPDdpPkKzNVE3OTR5PD;hQi=>
MT4	M1\GfWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M1;hZVczKGi{cx?=	MXrHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDNWFQh[2WubIOgbY5kfWKjdHXkJIZweiB5MjDodpMh[nliTWTTJIF{e2G7LDDHTVUxRTJ3zszN	M4e3Z\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MUG2NVQ4Lz5{M{GxOlE1PzxxYU6=
Huh7	NUn0UnFPSW62aY\pdoFtKGG\|c3H5		M1vpTVMh\GG7cx?=	NV[zd5o{SW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUEOYIHflco91gXCnIEHiJIlv\mWldHXkJIlvKGi3bXHuJGh2cDdiY3XscJMh[W[2ZYKgN{Bl[Xm\|IHL5JIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigSxiRVO1NF0yNjkQvF2=	NFzsUJA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUS5NFcxOCd-MkW0PVA4ODB:L3G+
HuH7	NFzaPI9EgXSxdH;4bYNqfHliYYPzZZk>		NUfk[4xUOyCmYYnz	M3jGVWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGh2UDdiY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBk\WyuII\pZYJqdGm2eTDh[pRmeiB\|IHThfZMh[nliQ3XscHRqfGW{IEm2JIF{e2G7LDDDR\|UxRTFzzszN	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR7MEewNEc,OjV2OUC3NFA9N2F-
Sf9	MkDFSpVv[3Srb36gZZN{[Xl?		MVO1JI1qdnN?	NYOyNWhXUW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBnfWyuLXzlcod1cCCqdX3hckBENXSncn3pcoFtKE[OQVetTIl{NXSjZ3fl[EBJTEGFMTDlfJBz\XO\|ZXSgbY4h[mGldXzveolzfXNiaX7m[YN1\WRiU3[5JIlve2WldDDj[YxteyC3c3nu[{BDd2NvTD3MfZMpSWNrLVHNR{BieyC\|dXLzeJJifGVicILlbY5kfWKjdHXkJIZweiB3IH3pcpMh\m:ubH;3[YQh[nlic4Xid5Rz[XSnIHHk[Il1cW:wIH3lZZN2emWmIHHmeIVzKDN3IH3pcpMh[nliZnz1c5Jme2OnLDDJR\|UxRTNwON88US=>	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDh\|NUe5Okc,Ojh6M{W3PVY9N2F-
Sf9	M2nYWmZ2dmO2aX;uJIF{e2G7		MWS1JI1qdnN?	Mn7nTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDoeY1idiCodXzsMYxmdme2aDDDMZRmem2rbnHsJGhqey22YXfn[YQhUESDQ{OgLFM6PSC2bzC0PFkhemW\|aXT1[ZMqN2i3bXHuJG5EV1J{IHX4dJJme3OnZDDpckBj[WO3bH;2bZJ2eyCrbn\lZ5Rm\CCVZkmgbY5{\WO2IHPlcIx{KHW\|aX7nJGJw[y2OLVz5d{hC[ylvQV3DJIF{KHO3YoP0doF1\SCycnX0doVifGWmIH\vdkA2KG2rboOg[o9tdG:5ZXSgZpkhe3Wkc4TyZZRmKGGmZHn0bY9vKG2nYYP1doVlNCCLQ{WwQVcvOc7:TR?=	NEjqeJU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEizOVc6Pid-Mki4N\|U4QTZ:L3G+
Sf9	MoLPSpVv[3Srb36gZZN{[Xl?		NWTyfHN5PSCvaX7z	MkjKTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDoeY1idiCodXzsMYxmdme2aDDDMZRmem2rbnHsJGhqey22YXfn[YQhUESDQ{Kg[ZhxemW\|c3XkJIlvKGKjY4Xsc5ZqenW\|IHnu[oVkfGWmIGPmPUBqdnOnY4SgZ4VtdHNidYPpcochSm:lLVytUJl{MEGlKT3BUWMh[XNic4Xid5Rz[XSnIIDy[Ylv[3WkYYTl[EBnd3JiNTDtbY5{KG[xbHzve4VlKGK7IIP1ZpN1emG2ZTDh[IRqfGmxbjDt[YF{fXKnZDDh[pRmeiB\|NTDtbY5{KGK7IH\seY9z\XOlZX7j[UBie3OjeTygTWM2OD1\|Md88US=>	NFHJT4M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEizOVc6Pid-Mki4N\|U4QTZ:L3G+
SH-SY5Y	NUSx[\|ROS3m2b4TvfIlkcXS7IHHzd4F6			MnG1R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV2guW1l3WTDj[YxteyCneIDy[ZN{cW6pIGTQOVMh[nliQ3XscHRqfGW{OU[gRXF2\W:3czDvcoUhe2:udYTpc44h[2WubDDwdo9tcW[ncnH0bY9vKGG\|c3H5	NX\DR\|U6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki4N\|U4QTZpPkK4PFM2Pzl4PD;hQi=>
IMR5	NXj5V5NDS3m2b4TvfIlkcXS7IHHzd4F6			MoHBR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTW1TPSClZXzsd{BmgHC{ZYPzbY5oKFSSNUOgZpkhS2WubGTpeIVzQTZiQWH1[Y92eyCxbnWgd49tfXSrb36gZ4VtdCCycn;sbYZmemG2aX;uJIF{e2G7	NVzSTW81RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki4N\|U4QTZpPkK4PFM2Pzl4PD;hQi=>
SK-N-AS	M2rNTWN6fG:2b4jpZ4l1gSCjc4PhfS=>			MYLDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTT{1PNUGVIHPlcIx{KGW6cILld5NqdmdiVGC1N{BufXSjdHnvckBjgSCFZXzsWIl1\XJ7NjDBVZVmd3W\|IH;u[UB{d2y3dHnvckBk\WyuIIDyc4xq\mW{YYTpc44h[XO\|YYm=	M4flZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OEO1O\|k3Lz5{OEizOVc6PjxxYU6=
Kelly	M2TRUGN6fG:2b4jpZ4l1gSCjc4PhfS=>			NXTVUppvS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hU2WubImgZ4VtdHNiZYjwdoV{e2mwZzDUVFU{KG23dHH0bY9vKGK7IFPlcIxVcXSnckm2JGFSfWWxdYOgc45mKHOxbIX0bY9vKGOnbHygdJJwdGmoZYLheIlwdiCjc4PhfS=>	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDh\|NUe5Okc,Ojh6M{W3PVY9N2F-
BE(2)-C	MVPDfZRwfG:6aXPpeJkh[XO\|YYm=		NGPZN284OiCqcoO=	MnrqR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRmUpOilvQzDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4h[2WubDD2bYFjcWyrdImgZpkhdWWjc4XybY5oKG2ndHHic4xq[yCjY4Tpeol1gSCjZoTldkA4OiCqcoOgZpkhX1OWLUigZZN{[XluIFnDOVA:OTlwOd88US=>	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTF7MEC5Nkc,OjlzOUCwPVI9N2F-
Sf9	NYrJOpRTTnWwY4Tpc44h[XO\|YYm=		MUK5NEBucW6\|	MV\Jcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IHj1cYFvKG[3bHygcIVv\3SqIFOteIVzdWmwYXygSmxCTy22YXfn[YQhUESDQ{Gg[ZhxemW\|c3XkJIlvKG[jbHygZZJugXexcn2gV4Y6KGOnbHzzJJV{cW6pIH\seY9zd2enbnnjJHpOSUxiYYOgd5Vje3S{YYTlJIFnfGW{IEmwJI1qdnNiYomg[ox2d3KrbXX0dolkKGGwYXz5d4l{NCCLQ{WwQVI5NjQQvF2=	NULmdJNYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmxPVAxQTJpPkK5NVkxODl{PD;hQi=>
Sf9	MYHGeY5kfGmxbjDhd5NigQ>?		M3\kWlkxKG2rboO=	Mn3zTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDoeY1idiCodXzsJIxmdme2aDDISGFEPiCneIDy[ZN{\WRiaX6g[oFtdCCjcn35e49zdSCVZkmgZ4VtdHNidYPpcoch\my3b4Lv[4VvcWNiWl3BUEBieyC\|dXLzeJJifGViYX\0[ZIhQTBibXnud{BjgSCobIXvdolu\XS{aXOgZY5idHm\|aYOsJGlEPTB;NEiuNu69VQ>?	Mn7mQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjlzOUCwPVIoRjJ7MUmwNFkzRC:jPh?=
BE(2)-C	MVnGeY5kfGmxbjDhd5NigQ>?	NY\abYdKPiC3TR?=	NUD6OJM1PzJiaILz	NWO2dZJDUW6qaXLpeIlwdiCxZjDISGFEQCCrbjDoeY1idiCERTiyLU1EKGOnbHzzJIF{e2W\|c3XkJIF{KHWycnXneYxifGmxbjDv[kBxOjFxQ1TLUlEh\2WwZTDlfJBz\XO\|aX;uJIF1KDZidV2gZYZ1\XJiN{KgbJJ{KGK7IGLUMXBEWiCjbnHsfZNqeyC{ZXzheIl3\SC2bzDjc451em:u	NV7a[pNpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmxPVAxQTJpPkK5NVkxODl{PD;hQi=>
BE(2)-C	MojUSpVv[3Srb36gZZN{[Xl?	NGnsRWU3KHWP	MmnWO\|IhcHK\|	NWm3VVRrUW6qaXLpeIlwdiCxZjDISGFEQCCrbjDoeY1idiCERTiyLU1EKGOnbHzzJIF{e2W\|c3XkJIF{KHWycnXneYxifGmxbjDv[kBVemuDL17UVmsyKGenbnWg[ZhxemW\|c3nvckBifCB4IIXNJIFnfGW{IEeyJIhzeyCkeTDSWE1RS1JiYX7hcJl{cXNicnXsZZRqfmVidH:gZ49vfHKxbB?=	MlS4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjlzOUCwPVIoRjJ7MUmwNFkzRC:jPh?=
BE(2)-C	M{HOeGZ2dmO2aX;uJIF{e2G7	MV:2JJVO	MVG3NkBpenN?	NGDUZWZKdmirYnn0bY9vKG:oIFjERWM5KGmwIHj1cYFvKEKHKEKpMWMh[2WubIOgZZN{\XO\|ZXSgZZMhfXC{ZXf1cIF1cW:wIH;mJHRJKGenbnWg[ZhxemW\|c3nvckBifCB4IIXNJIFnfGW{IEeyJIhzeyCkeTDSWE1RS1JiYX7hcJl{cXNicnXsZZRqfmVidH:gZ49vfHKxbB?=	Mke3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjlzOUCwPVIoRjJ7MUmwNFkzRC:jPh?=
BE(2)-C	M1fJdWZ2dmO2aX;uJIF{e2G7	NIP5XY43KHWP	MUC2JIRigXN?	M2iyVWlv\HWldHnvckBw\iCxdYTndo94fGhib3[gcoV2em:oaXzhcYVvfCCyb4PpeIl3\SCwZYX0dol1\S2uaXvlJJN1enWldIXy[ZMhcW5iaIXtZY4hSkVqMjmtR{Bk\WyuczDheEA3KHWPIHHmeIVzKDZiZHH5d{BjgSCGQWDJMZN1[WmwaX7nJIJie2WmIH3pZ5Jwe2OxcHnjJIFv[Wy7c3nz	NX:5eWQxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmxPVAxQTJpPkK5NVkxODl{PD;hQi=>
A673	M4m0XZFJXFNiYYPzZZk>			NX3obHdjeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFG2O\|Mh[2WubIO=	NXXsNWdwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-MC	M4LXUZFJXFNiYYPzZZk>			M1HORpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMW1EKGOnbHzz	M{exSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB-EBc1	MX3xTHRUKGG\|c3H5			MoLOdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6ELVXCZ\|Eh[2WubIO=	M3;pflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-SH	M37TOZFJXFNiYYPzZZk>			Mn73dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tV2gh[2WubIO=	M4fVWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB1643	MUfxTHRUKGG\|c3H5			Mn;BdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6EMU[0N{Bk\Wyucx?=	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
LAN-5	M{j6RpFJXFNiYYPzZZk>			NXviOm1ReUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFzBUk02KGOnbHzz	NGrwUHU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
Jurkat	NX\qUJRySW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=			NXP6VolISW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDKeZJs[XRiY3XscJMh[nliYXzhcYFzKGKudXWgZZN{[XluIFfJOVA:Oi52zszN	MoLXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl3MEW5N\|UoRjJ7NUC1PVM2RC:jPh?=
HUT78	NULQTGVlSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=			NXXYfpJHSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIWXQ4QCClZXzsd{BjgSCjbHHtZZIh[my3ZTDhd5NigSxiR1m1NF0zNjUQvF2=	NETzWFQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUWwOVk{PSd-Mkm1NFU6OzV:L3G+
HSB2	NHztUI1CdnSrcILvcIln\XKjdHn2[UBie3OjeR?=			NHHwV3hCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjTRlIh[2WubIOgZpkh[WyjbXHyJIJtfWViYYPzZZktKEeLNUC9Nk41\|ryP	NHGzU3c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUWwOVk{PSd-Mkm1NFU6OzV:L3G+
MOLT4	MnTPRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?			NI[1[lhCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3PUHQ1KGOnbHzzJIJ6KGGuYX3hdkBjdHWnIHHzd4F6NCCJSUWwQVIvPM7:TR?=	MnHaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl3MEW5N\|UoRjJ7NUC1PVM2RC:jPh?=
Jurkat	MWLBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NG\ZeHA1QCCqcoO=	MlTQRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCMdYLrZZQh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OD12LkZOwG0>	NVTseJp[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm1N\|M5PzNpPkK5OVM{QDd\|PD;hQi=>
MOLT4	NH3zd49CdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NHTNfHo1QCCqcoO=	M1K3U2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTV;MWFQh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OD17LkVOwG0>	NXztSHVURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm1N\|M5PzNpPkK5OVM{QDd\|PD;hQi=>
HEL	NIT6bIRCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NEGyO401QCCqcoO=	Mn25RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKRVygZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0yOC56zszN	NGrIWpI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUWzN\|g4Oyd-Mkm1N\|M5PzN:L3G+
SK-N-BE(2)	MVLBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		M1TXTVQ5KGi{cx?=	MVrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFONLV6tRmUpOiliY3XscJMh[W[2ZYKgOFghcHK\|IHL5JG1VXCCjc4PhfUwhUUN3ME2xOk46\|ryP	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTV\|M{i3N{c,Ojl3M{O4O\|M9N2F-
PC3	M3TJbGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NGfXOJA1QCCqcoO=	NVvyeZZbSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDQR\|Mh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1zOT6y{txO	MlK5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl3M{O4O\|MoRjJ7NUOzPFc{RC:jPh?=
K562	M3jRWGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NVTtdJQ5PzJiaILz	MkLlRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCNNU[yJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCPVGOgZZN{[XluIFfJOVA:Oi5yMd88US=>	NF61bWw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MECwOFY6Pyd-M{CwNFQ3QTd:L3G+
K562R	NW[4PWZoSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MoDUO\|IhcHK\|	M1T5bGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iS{W2NnIh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UV{Bie3OjeTygS2k2OD1{LkNOwG0>	MmLEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByMES2PVcoRjNyMEC0Olk4RC:jPh?=
HCT116	MojDRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NV70SVJ7PzJiaILz	NHzOUXpCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjDWFEyPiClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRUKGG\|c3H5MEBIUTVyPUKuOlTPxE1?	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODByNE[5O{c,OzByMES2PVc9N2F-
PC3	NGX6fZlCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MmrDO\|IhcHK\|	NWDVNWpYSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDQR\|Mh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UV{Bie3OjeTygS2k2OD1{Lk[2{txO	NH;UNow9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MECwOFY6Pyd-M{CwNFQ3QTd:L3G+
MCF7	MojTRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NFzjT204OiCqcoO=	NYjxXVVqSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHMh[XO\|YYmsJGdKPTB;Mj65O:69VQ>?	M2XCclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMEC0Olk4Lz5\|MECwOFY6PzxxYU6=
BL21 (DE3)	NHPiW\|BHfW6ldHnvckBie3OjeR?=			MVHCbY5lcW6pIHHm[olvcXS7IITvJIh2dWGwIFjpd{11cGmxcnXkc5hqdi22YXfn[YQhUESDQ{ig[ZhxemW\|c3XkJIlvKEW\|Y3jldolkcGmjIHPvcIkhSkx{MTCoSGU{MSClZXzsd{BjgSCLVFOgcYV1cG:mLDDL[F0xNjB5NUJOwG0>	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODN2N{G0PEc,OzB\|NEexOFg9N2F-
BL21 (DE3)	M1v4WWZ2dmO2aX;uJIF{e2G7			NHzUb3ZKdmirYnn0bY9vKG:oIHj1cYFvKEircz30bIlwemWmb4jpck11[WepZXSgTGRCSzhiZYjwdoV{e2WmIHnuJGV{[2incnnjbIliKGOxbHmgRmwzOSBqRFWzLUBk\WyuczD1d4lv\yCIbIXvdkBl\SCOeYOgLHIqNUiGQVO4JIF{KHO3YoP0doF1\SCkeTDmcJVwem:vZYTybYMhdWW2aH;kMEBKSzVyPUCuNFc4P87:TR?=	M4HUT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyM{S3NVQ5Lz5\|MEO0O\|E1QDxxYU6=
BL21 (DE3)	NITWRXlHfW6ldHnvckBie3OjeR?=			NWfBVZI2SmmwZHnu[{Bi\m[rbnn0fUB1dyCVY3jpd5Rwe2:vYTDtZY5{d26rIFjpd{11[WepZXSgTGRCSzhiZYjwdoV{e2WmIHnuJGV{[2incnnjbIliKGOxbHmgRmwzOSBqRFWzLUBk\WyuczDifUBKXENibXX0bI9lNCCNZE2wMlM3P87:TR?=	NET5S2o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEO0O\|E1QCd-M{CzOFcyPDh:L3G+
BL21 (DE3)	M3XDXmZ2dmO2aX;uJIF{e2G7			MlznTY5pcWKrdHnvckBw\iCVY3jpd5Rwe2:vYTDtZY5{d26rIFjpd{11[WepZXSgTGRCSzhiZYjwdoV{e2WmIHnuJGV{[2incnnjbIliKGOxbHmgRmwzOSBqRFWzLUBk\WyuczD1d4lv\yCIbIXvdkBl\SCOeYOgLHIqNUiGQVO4JIF{KHO3YoP0doF1\SCkeTDmcJVwem:vZYTybYMhdWW2aH;kMEBKSzVyPUCuOFM2QM7:TR?=	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODN2N{G0PEc,OzB\|NEexOFg9N2F-
BL21 (DE3)	MWrGeY5kfGmxbjDhd5NigQ>?			MUjJcohq[mm2aX;uJI9nKGi3bXHuJGhqey22aHnvdoVld3irbj30ZYdo\WRiSFTBR\|ghdUx4L1yxO\|lKKG23dHHueEBmgHC{ZYPz[YQhcW5iRYPjbIVzcWOqaXGgZ49tcSCETEKxJEhFTTNrIHPlcIx{KHW\|aX7nJGZtfW:{IHTlJGx6eyBqUjmtTGRCSzhiYYOgd5Vje3S{YYTlJIJ6KG[udX;yc41mfHKrYzDt[ZRpd2RuIFnDOVA:Oc7:TR?=	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODN2N{G0PEc,OzB\|NEexOFg9N2F-
BL21 (DE3)	MojPSpVv[3Srb36gZZN{[Xl?			M17DXWlvcGmkaYTpc44hd2ZiaIXtZY4hUGm\|LYTobY9z\WSxeHnuMZRi\2enZDDISGFEQCCvTE[gcZV1[W62IHX4dJJme3OnZDDpckBGe2OqZYLpZ4hq[SClb3zpJGJNOjFiKFTFN{kh[2WubIOgeZNqdmdiRnz1c5Ih\GViTInzJEhTMS2KRFHDPEBieyC\|dXLzeJJifGViYomg[ox2d3KxbXX0dolkKG2ndHjv[EwhUUN3ME2xMlY{\|ryP	M2XEXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyM{S3NVQ5Lz5\|MEO0O\|E1QDxxYU6=
BL21 (DE3)	MV3GeY5kfGmxbjDhd5NigQ>?			NXrmRVJxUW6qaXLpeIlwdiCxZjDoeY1idiCKaYOteIhqd3KnZH;4bY4ufGGpZ3XkJGhFSUN6IH3MNU9uVDZibYX0ZY51KGW6cILld5Nm\CCrbjDFd4Np\XKrY3jpZUBkd2yrIFLMNlEhMESHMzmgZ4VtdHNidYPpcochTmy3b4Kg[IUhVHm\|IDjSLU1JTEGFODDhd{B{fWK\|dILheIUh[nliZnz1c5JwdWW2cnnjJI1mfGixZDygTWM2OD1{LkhOwG0>	NHnLV5U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEO0O\|E1QCd-M{CzOFcyPDh:L3G+
BL21 (DE3)	MmG1SpVv[3Srb36gZZN{[Xl?			NW\LVmR4UW6qaXLpeIlwdiCxZjDoeY1idiCKaYOteIhqd3KnZH;4bY4ufGGpZ3XkJGhFSUN6IH3MNU9uVDZxTEG3PWkhdXW2YX70JIV5eHKnc4Pl[EBqdiCHc3Po[ZJq[2irYTDjc4xqKEKOMkGgLGRGOyliY3XscJMhfXOrbnegSox2d3JiZHWgUJl{KCiUKT3ISGFEQCCjczDzeYJ{fHKjdHWgZpkh\my3b4LvcYV1emmlIH3leIhw\CxiSVO1NF02\|ryP	M{PnelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyM{S3NVQ5Lz5\|MEO0O\|E1QDxxYU6=
Sf9	NF75[FZHfW6ldHnvckBie3OjeR?=			NGPTTZRKdmirYnn0bY9vKG:oIFOteIVzdWmwYXygSmxCTy:KaYOteIFo\2WmIH\1cIwhdGWwZ4ToJIh2dWGwIFjERWMyKGW6cILld5Nm\CCrbjDiZYN2dG:4aYL1d{Bqdm[nY4Tl[EBU\jliaX7z[YN1KGOnbHzzJJV{cW6pIGqoRYMqVHm\|LVHNR{BieyC\|dXLzeJJifGViYomg[ox2d3KxbXX0dolkKG2ndHjv[EwhUUN3ME2yPE4{\|ryP	NH7FXIY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEO0O\|E1QCd-M{CzOFcyPDh:L3G+
Sf9	NEjETI9HfW6ldHnvckBie3OjeR?=			MkD6TY5pcWKrdHnvckBw\iCQLYTldo1qdmGuIFfTWE11[WepZXSg[pVtdCCuZX7neIghcHWvYX6gTGRCSzZiZYjwdoV{e2WmIHnuJIJi[3Wub4\pdpV{KGmwZnXjeIVlKFOoOTDpcpNm[3RiY3XscJMhfXOrbnegXkhC[ymOeYOtRW1EKGG\|IIP1ZpN1emG2ZTDifUBndHWxcn;t[ZRzcWNibXX0bI9lNCCLQ{WwQVQ5NjMQvF2=	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODN2N{G0PEc,OzB\|NEexOFg9N2F-
Sf9	M163fmZ2dmO2aX;uJIF{e2G7		NXmyfXRVPDBibXnudy=>	M{DCVWlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgbJVu[W5iZoXscEBt\W6pdHigR{11\XKvaX7hcEBJcXNvdHHn[4VlKEiGQVO4JIV5eHKnc4Pl[EBqdiCkYXP1cI93cXK3czDpcoZm[3SnZDDpcpNm[3RiY3XscJMhdWWjc4Xy[YQh[W[2ZYKgOFAhdWmwczDifUBJTEGFLVfsc\|EwOiCudX3pcoV{[2WwdDDhd5NigSxiSVO1NF0xNjB\|MU[y{txO	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODl4NEK5NEc,OzB7NkSyPVA9N2F-
SK-N-BE(2)C	MkHqRY51cWOub37v[4VvcWNiYYPzZZk>		NYr1VGluQTZiaILz	NVnkN\|MxSW62aXPsc45w\2WwaXOgZYN1cX[rdImgbY4hcHWvYX6gV2suVi2ERTiyLWMh[2WubIOgZZN{\XO\|ZXSgZZMhemWmdXP0bY9vKGmwIHPlcIwheHKxbHnm[ZJifGmxbjDpcoN2[mG2ZXSg[o9zKDl4IHjyd{BjgSClconzeIFtKH[rb3zleEB{fGGrbnnu[{Bj[XOnZDDhd5NigSxiR1m1NF0yPc7:TR?=	MlW4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzF4M{CwOVQoRjNzNkOwNFU1RC:jPh?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Immunofluorescence	SMC3 / Ac-SMC3 ; PubMed: 27072133 J Biol Chem A and B, representative immunofluorescence analysis of total- and ac-SMC3 in G1-S synchronized MCF7 cells treated with the indicated concentrations of PCI-34051 for 6 and 12 h, respectively. MCF7 cells grown in complete medium were synchronized to G1-S phase by double thymidine block and released in the presence of different concentrations of PCI-34051 for 6 or 12 h. Cells were stained for DNA (Hoechst-H33342, blue) and with antibodies detecting total-SMC3 (green) and ac-SMC3 (red). Cells were analyzed by Nikon C2 confocal microscope; images were taken at 20× magnification (z-series) using the NIS elements software, z-stacked, and processed using FIJI.	27072133

激酶实验：^[1]	- 合并组蛋白去乙酰化酶活性: 使用96孔实验板上，反应体积为100 μL，在荧光酶标仪上测量PCI-34051特性。HDAC 蛋白在反应buffer (50 mM HEPES, 100 mM KCl, 0.001% Tween-20, 5% DMSO, pH7.4,伴有牛血清蛋白，浓度为0-0.05%)中与不同浓度PCI-34051混合，再温育15分钟，测定每种酶。加入胰蛋白酶，终浓度为50 nM,加入乙酰基-gly-Ala-(N-乙酰基-Lys)-氨基-4-甲基香豆素，终浓度为25-100 μM，开始反应。停滞30分钟后, 使用激发波长为335 nm，检测波长为460 nm，在30分钟时间范围测量荧光值。测量的荧光值的增量用了衡量反应速率。
细胞实验：^[1]	- 合并 Cell lines: A549 细胞系, Ovcar-3 细胞系 Concentrations: 5 μM Incubation Time: 24 小时 Method: 肿瘤细胞系和人脐静脉内皮细胞培养至少两次倍增时间，PCI-34051处理末期，通过Alamar Blue荧光细胞增殖检测实验监测生长。PCI-34051重复三份加入96孔板中。使用四参数方程，通过非线性回归估量抑制 50% 细胞生长所需浓度(GI50)和95%置信区间。 (Only for Reference)

参考文献

[1] Balasubramanian S, et al. Leukemia. 2008, 22(5), 1026-1034.

溶解度 (25°C)

体外	DMSO	59 mg/mL (199.1 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 5% DMSO+40%PEG300+5% tween80+50% H2O	5 mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download PCI-34051 SDF

分子量	296.32
化学式	C₁₇H₁₆N₂O₃
CAS号	950762-95-5
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	N/A

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

泛HDAC抑制剂

Panobinostat (LBH589) : Pan-HDAC inhibitor, IC50=5 nM.
活性最高的HDAC抑制剂

Quisinostat (JNJ-26481585) : HDAC1, IC50=0.11 nM; HDAC2, IC50=0.33 nM.
FDA批准的HDAC抑制剂

Vorinostat (SAHA, MK0683) : Approved by FDA against cutaneous T cell lymphoma.
最新的HDAC抑制剂

RG2833 (RGFP109) ^New : Brain-penetrant HDAC inhibitor with IC50 of 60 nM and 50 nM for HDAC1 and HDAC3, respectively.

研究领域

产品类型

定制您的化合物库

PCI-34051

客户使用Selleck生产的PCI-34051发表文献38篇：

产品安全说明书

HDAC抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download PCI-34051 SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

技术支持

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

相关HDAC产品